2 active not recruiting, 2 completed, 1 recruiting. 3 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Alkeus Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ALK-001 on the Progression of Stargardt Disease ALK-001, Placebo - Stargardt Disease | Phase 3 | Recruiting | Alkeus Pharmaceuticals, Inc. | 230 | 2026-06-03 | 2026-09-18 |
| Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE) ALK-001 - Stargardt Disease, Stargardt Macular Degeneration | Phase 2 | Active not recruiting | Alkeus Pharmaceuticals, Inc. | 200 | 2019-12-20 | 2026-09-21 |
| Phase 2/3 Study of ALK-001 in Geographic Atrophy ALK-001 oral capsule, Placebo oral capsule - Geographic Atrophy, Age Related Macular Degeneration | Phase 2 / Phase 3 | Completed | Alkeus Pharmaceuticals, Inc. | 200 | 2019-05-07 | 2025-11-03 |
| Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease ALK-001, Placebo - Stargardt Disease, Stargardt Macular Degeneration | Phase 2 | Active not recruiting | Alkeus Pharmaceuticals, Inc. | 160 | 2015-08-01 | 2026-09-21 |
| Phase 1 Safety Study of ALK-001 in Healthy Volunteers ALK-001 (No generic name) - Stargardt Disease, Age-related Macular Degeneration | Phase 1 | Completed | Alkeus Pharmaceuticals, Inc. | 40 | 2014-04-01 | 2025-04-27 |
Stargardt Disease (4) · Macular Degeneration (2) · Geographic Atrophy (1)
United States (4)